OncBioMune Signs Work Order for Phase 2 Clinical Trial of ProscaVax for Late Stage Prostate Cancer
October 16, 2018 12:35 ET
|
OncBioMune, L.L.C.
BATON ROUGE, La., Oct. 16, 2018 (GLOBE NEWSWIRE) -- OncBioMune Pharmaceuticals, Inc. (OTCQB:OBMP) ("OncBioMune" or the "Company"), a clinical-stage biopharmaceutical company engaged in the...
OncBioMune Advancing ProscaVax Towards Second Phase 2 Clinical Trial for Prostate Cancer with Protocol Submission to FDA
October 11, 2018 09:36 ET
|
OncBioMune, L.L.C.
BATON ROUGE, La., Oct. 11, 2018 (GLOBE NEWSWIRE) -- OncBioMune Pharmaceuticals, Inc. (OTCQB:OBMP) ("OncBioMune" or the "Company"), a clinical-stage biopharmaceutical company engaged in the...
OncBioMune Initiates Phase 2 Clinical Trial of Novel Vaccine as Front-Line Treatment for Prostate Cancer
September 27, 2018 09:51 ET
|
OncBioMune, L.L.C.
BATON ROUGE, La., Sept. 27, 2018 (GLOBE NEWSWIRE) -- OncBioMune Pharmaceuticals, Inc. (OTCQB:OBMP) ("OncBioMune" or the "Company"), a clinical-stage biopharmaceutical company engaged in the...
OncBioMune’s Phase 2 Clinical Trial of ProscaVax for Early-Stage Prostate Cancer is Now Included on ClinicalTrials.gov
July 09, 2018 11:31 ET
|
OncBioMune, L.L.C.
BATON ROUGE, La., July 09, 2018 (GLOBE NEWSWIRE) -- OncBioMune Pharmaceuticals, Inc. (OTCQB:OBMP) ("OncBioMune" or the "Company"), a clinical-stage biopharmaceutical company engaged in the...
OncBioMune Signs Work Order for Phase 2 Clinical Trial of ProscaVax for Early Stage Prostate Cancer
July 02, 2018 14:37 ET
|
OncBioMune, L.L.C.
BATON ROUGE, La., July 02, 2018 (GLOBE NEWSWIRE) -- OncBioMune Pharmaceuticals, Inc. (OTCQB:OBMP) ("OncBioMune" or the "Company"), a clinical-stage biopharmaceutical company engaged in the...
OncBioMune to Commence Phase 2 Trial of ProscaVax for Early Stage Prostate Cancer Patients
June 20, 2018 08:00 ET
|
OncBioMune, L.L.C.
BATON ROUGE, La., June 20, 2018 (GLOBE NEWSWIRE) -- OncBioMune Pharmaceuticals, Inc. (OTCQB:OBMP) ("OncBioMune" or the "Company"), a clinical-stage biopharmaceutical company engaged in the...
OncBioMune Returns Protocol to Scientific Review Committee Overseeing Phase 2 Prostate Cancer Clinical Trial
March 28, 2018 09:10 ET
|
OncBioMune, L.L.C.
BATON ROUGE, La., March 28, 2018 (GLOBE NEWSWIRE) -- OncBioMune Pharmaceuticals, Inc. (OTCQB:OBMP) ("OncBioMune" or the "Company"), a clinical-stage biopharmaceutical company engaged in the...
Scientific Review Committee Meets on OncBioMune’s Phase 2 Prostate Cancer Clinical Trial
March 22, 2018 09:00 ET
|
OncBioMune, L.L.C.
BATON ROUGE, La., March 22, 2018 (GLOBE NEWSWIRE) -- OncBioMune Pharmaceuticals, Inc. (OTCQB:OBMP) ("OncBioMune" or the "Company"), a clinical-stage biopharmaceutical company engaged in the...
OncBioMune Announces Presentation at the 2018 AACR Annual Meeting
March 20, 2018 09:04 ET
|
OncBioMune, L.L.C.
BATON ROUGE, La., March 20, 2018 (GLOBE NEWSWIRE) -- OncBioMune Pharmaceuticals, Inc. (OTCQB:OBMP) ("OncBioMune" or the "Company"), a clinical-stage biopharmaceutical company engaged in the...
OncBioMune Appoints Robert Neal Holcomb to Board of Directors
March 19, 2018 09:23 ET
|
OncBioMune, L.L.C.
BATON ROUGE, La., March 19, 2018 (GLOBE NEWSWIRE) -- OncBioMune Pharmaceuticals, Inc. (OTCQB:OBMP) ("OncBioMune" or the "Company"), a clinical-stage biopharmaceutical company engaged in the...